Thyroid-associated orbitopathy and biomarkers: Where we are and what we can hope for the future

35Citations
Citations of this article
67Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. Thyroid-associated orbitopathy (TAO) is the most common autoimmune disease of the orbit. It occurs more often in patients presenting with hyperthyroidism, characteristic of Graves' disease, but may be associated with hypothyroidism or euthyroidism. The diagnosis of TAO is based on clinical orbital features, radiological criteria, and the potential association with thyroid disease. To date, there is no specific marker of the orbital disease, making the early diagnosis difficult, especially if the orbital involvement precedes the thyroid dysfunction. Summary. The goal of this review is to present the disease and combine the available data in the literature concerning investigation of TAO biomarkers. Conclusions. Despite the progress done in the understanding of TAO disease, some important pieces are still missing. Typically, for the future, major efforts have to be done in the discovery of new biomarkers, validation of the suspected candidates on multicenter cohorts with standardized methodologies, and establishment of their clinical performances on the specific clinical application fields in order to improve not only the management of the TAO patients but also the therapeutic options and follow-up.

Cite

CITATION STYLE

APA

Turck, N., Eperon, S., De Los Angeles Gracia, M., Obéric, A., & Hamédani, M. (2018). Thyroid-associated orbitopathy and biomarkers: Where we are and what we can hope for the future. Disease Markers, 2018. https://doi.org/10.1155/2018/7010196

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free